探讨舍曲林治疗冠心病(CHD)介入术后合并抑郁症的临床疗效
To investigate the clinical efficacy of sertraline in the treatment of coronary heart disease (CHD) after intervention for depression
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2020, 47(2) |
| 作者 |
|
| 作者单位 |
河南省濮阳市人民医院 心内科 ;
|
| 摘要 |
目的：探讨舍曲林治疗冠心病术后合并抑郁症的临床疗效。方法：以2016年1月至2019年1月为时间段，选取我院收治的CHD介入术后合并抑郁症患者200例，随机分为2组，各100例。采用安慰剂治疗对照组，采用舍曲林治疗观察组。比较两组治疗前后HAMD、HAMA评分、血清 IL-18、MPO等指标变化、疗效、生存质量。结果：在HAMD、HAMA评分上，两组治疗前对比无统计学差异（P<0.05）；而治疗后二者对比存在统计学差异（P<0.05）。在血清MPO、IL-18等指标上，两组治疗前对比无统计学差异（P<0.05）；而治疗后二者对比存在统计学差异（P<0.05）。在治疗有效率上，对照组总体为82.0%，观察组总体为97.0%，二者对比存在统计学差异（P<0.05）。在生存质量上，两组生理、社会、躯体功能、情感职能等评分对比存在统计学差异（P<0.05）。结论：舍曲林治疗冠心病术后合并抑郁症的疗效十分显著，即可显著改善患者各种症状，消除负性情绪，还能改善其血清指标和生存质量，利于其预后康复，因此值得推广和应用
|
| Abstract |
Objective: To investigate the clinical efficacy of sertraline in the treatment of postoperative depression with coronary heart disease. Methods: From January 2016 to January 2019, 200 patients with depression after CHD intervention were enrolled in our hospital. They were randomly divided into 2 groups, 100 cases each. The control group was treated with placebo and treated with sertraline. The changes of HAMD, HAMA score, serum IL-18 and MPO before and after treatment were compared between the two groups. RESULTS: There was no significant difference in the HAMD and HAMA scores between the two groups (P<0.05). There was a statistically significant difference between the two groups (P<0.05). There were no significant differences in serum MPO, IL-18 and other indicators before treatment (P<0.05). There was significant difference between the two groups (P<0.05). In the treatment efficiency, the control group was 82.0% overall, and the observation group was 97.0% overall. There was a statistical difference between the two groups (P<0.05). In terms of quality of life, there were statistical differences in the scores of physiological, social, physical and emotional functions between the two groups (P<0.05). Conclusion: Sertraline is effective in treating depression after coronary heart disease, which can significantly improve various symptoms, eliminate negative emotions, improve serum index and quality of life, and facilitate its prognosis. Therefore, it is worth promoting. And application.
|
| 关键词 |
冠心病；介入手术；抑郁症；舍曲林；临床疗效
|
| KeyWord |
coronary heart disease; interventional surgery; depression; sertraline; clinical efficacy
|
| 基金项目 |
|
| 页码 |
376-378 |
陈雪斌*.
探讨舍曲林治疗冠心病(CHD)介入术后合并抑郁症的临床疗效 [J].
国际精神病学杂志.
2020; 47; (2).
376 - 378.